Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation

Lung Cancer

Volumn 16, Issue 2-3, 1997, Pages 229-238

  Segawa, Yoshihiko ^a   Takigawa, Nagio ^a   Mandai, Koichi ^a   Maeda, Yoshinobu ^a   Takata, Ichiro ^a   Fujimoto, Nobukazu ^a   Jinno, Kenji ^a  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

enzyme linked immunosorbent assay; immunohistochemistry; lung cancer; p53 gene; serum p53 protein; small cell lung cancer

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0030975812     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)82785-7     Document Type: Article

References (15)

1. Chang F, Syrjänen S, Syrjänen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995; 13: 1009-1022.
2. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318-1327.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
4. Hyde L, Yee J, Wilson R, Patno ME. Cell type and the natural history of lung cancer. J Am Med Assoc 1965; 193: 52-54.
5. Johnson BE. Biology of lung cancer. In: Johnson BE, Johnson DH, editors. Lung cancer. New York: Wiley-Liss Inc, 1995; 15-40.
6. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, Hittelman WN, Hong WK. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995; 13: 1893-1903.
7. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
8. Luo JC, Zehab R, Anttila S, Ridanpaa M, Husgafvel-Pursiainen K, Vainio H, Carney W, DeVivo I, Milling C, Brandt-Rauf PW. Detection of serum p53 protein in lung cancer patients. J Occup Med 1994; 36: 155-160.
9. Metz CE, Shen JH, Herman BA. New methods for estimating a binormal ROC curve from continuously-distributed test results. Invited for presentation at the 1990 Joint Statistical Meeting of the American Statistical Society and the Biometric Society, Anaheim, CA, August, 1990.
10. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M, Leinster SJ. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 1994; 69: 1115-1119.
11. Rosanelli GP, Wirnsberger GH, Purstner P, Steindorfer P. DNA flow cytometry and immunohistochemical demonstration of mutant p53 protein versus TPS and mutant p53 protein serum levels in human breast cancer. Proc Am Assoc Cancer Res 1993; 34: 227.
12. Sagman U, Lishner M, Maki E, Shepherd FA, Haddad R, Evans WK, DeBoer G, Payne D, Pringle JF, Yeoh JL, Ginsberg R, Feld R. Second primary malignancies following diagnosis of small-cell lung cancer. J Clin Oncol 1992; 10: 1525-1533.
13. Segawa Y, Ohnoshi T, Hiraki S, Ueoka H, Kiura K, Kamei H, Tabata M, Shibayama T, Miyatake K, Genba K, Matsumura T, Kimura I. Immunohistochemical detection of p-glycoprotein and carcinoembryonic antigen in small cell lung cancer: with reference to predictability of response to chemotherapy. Acta Med Okayama 1993; 47: 181-189.
14. Segawa Y, Ohnoshi T, Ueoka H, Miyake K, Takigawa N, Kimura I, Hiraki S, Fujii M, Machida K, Moritaka T. Double cancer in small cell lung cancer patients treated with intensive chemotherapy with or without radiation therapy. Jpn J Thorac Dis 1991; 29: 1432-1438.
15. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be development on the type of p53 mutation. Cancer Res 1992; 52: 4168-4174.